Skip to main content
Midas Edge

Indaptus Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 12, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 12, 2024

INDP$2.90-7.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Unaudited Condensed Consolidated Statements of Stockholders’ Equity

Common stock · Additional Paid In · Accumulated · Other Comprehensive
Shares · Amount · Capital · Deficit · Income (Loss) · Total
Balance, January 1, 20238,401,047$84,011$54,443,705$(29,993,685)$96,434$24,630,465
Stock-based compensation--727,144--727,144
Reclassification adjustment for interest earned on marketable securities included in net loss----(129,229)(129,229)
Change in unrealized gain on marketable securities----210,252210,252
Net loss---(4,253,238)-(4,253,238)
Balance, March 31, 20238,401,04784,01155,170,849(34,246,923)177,45721,185,394
Stock-based compensation--728,466--728,466
Reclassification adjustment for interest earned on marketable securities included in net loss----(161,197)(161,197)
Change in unrealized gain on marketable securities----117,895117,895
Net loss---(3,245,065)-(3,245,065)
Balance June 30, 20238,401,04784,01155,899,315(37,491,988)134,15518,625,493
Stock-based compensation--764,803--764,803
Reclassification adjustment for interest earned on marketable securities included in net loss----(140,567)(140,567)
Change in unrealized gain on marketable securities----6,4126,412
Net loss---(3,922,388)-(3,922,388)
Balance September 30, 20238,401,047$84,011$56,664,118$(41,414,376)$-$15,333,753
Balance, January 1, 20248,401,047$84,011$57,409,643$(45,417,156)$-$12,076,498
Stock-based compensation--774,691--774,691
Issuance of shares of common stock, net of issuance costs (Note 6b)137,8361,378314,669--316,047
Net loss---(3,806,677)-(3,806,677)
Balance, March 31, 20248,538,88385,38958,499,003(49,223,833)-9,360,559
Stock-based compensation--782,852--782,852
Issuance of shares of common stock, net of issuance costs (Note 6b)14,16414237,922--38,064
Net loss---(4,015,267)-(4,015,267)
Balance, June 30, 20248,553,04785,53159,319,777(53,239,100)-6,166,208
Stock-based compensation--444,184--444,184
Issuance of shares of common stock and warrants, net of issuance costs (Note 6c)1,643,83716,4382,445,532--2,461,970
Net loss---(3,069,036)-(3,069,036)
Balance, September 30, 202410,196,884$101,969$62,209,493$(56,308,136)$-$6,003,326
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.